arrow_back Back to App

Increased Diversity in Clinical Trials: New Rules for Patients

This new law aims to increase diversity in clinical trial participants to better reflect the U.S. population. This means drugs and therapies will be tested on a broader range of people, potentially leading to safer and more effective solutions for everyone. The act also introduces conveniences for patients participating in trials, such as fewer visits or remote contact options.
Key points
Clinical trials will need to include diverse participants based on race, ethnicity, age, and sex, ensuring treatments are better suited for various population groups.
Trial participants may benefit from less burdensome follow-up visits, such as phone calls, online options, or more convenient hours, making participation easier.
A national public awareness campaign will be launched to highlight the importance of diversity in clinical trials and encourage more people to participate.
The act mandates a study on financial barriers for trial participants, potentially leading to reimbursement for travel costs or compensation for time spent.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3503
Sponsor: Rep. Kelly, Robin L. [D-IL-2]
Process start date: 2023-05-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

NIH Clinical Trial Diversity Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3503.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-05-18.

What are the main provisions?

Key points include:

  • Clinical trials will need to include diverse participants based on race, ethnicity, age, and sex, ensuring treatments are better suited for various population groups.
  • Trial participants may benefit from less burdensome follow-up visits, such as phone calls, online options, or more convenient hours, making participation easier.
  • A national public awareness campaign will be launched to highlight the importance of diversity in clinical trials and encourage more people to participate.
  • The act mandates a study on financial barriers for trial participants, potentially leading to reimbursement for travel costs or compensation for time spent.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Kelly, Robin L. [D-IL-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health